natgillin/translations-raw huggingface dataset:
500 q12h 200 q8h ↑ 77%
500 svakih 12h 200 svakih 8h ↑ 77
500 tablets
500 tableta
500 to 1,000 mg once daily(2)
500 do 1000 mg jedanput na dan(2)
500 Units
500 jedinica
500 Units of C1 inhibitor in a colourless glass vial (Type I), sealed with a rubber stopper (Type I) and an aluminium seal with a plastic flip-off cap.
500 jedinica inhibitora C1 u bočici od bezbojnog stakla (tip I), zatvorenoj gumenim čepom (tip I) i aluminijskim prstenom s plastičnim poklopcem.
500 µg in 1 ml
500 µg u 1 ml
500 μg/5ml
500 μg/5 ml
500-1,000 µg/l
500-1000 µg/l
500/100 micrograms.
500/100 mikrograma.
500/200 mg twice daily
500/200 mg dva puta
500/200 mg twice daily
Tipranavir/ritonavir 500/200 mg dva puta dnevno
5000 doses
5000 doza
5000 doses
doza
5000 IU/ ml
5000 IU / ml
5000 IU/0.5 ml
20 000 IU/0,5 ml
5000 IU/0.5 ml
4000 IU/0,4 ml
5000 IU/0.5 ml
5 000 IU/0,5 ml
5000 IU/0.5 ml
Eporatio
5000 microgram (mcg/ml) for patients >2 years of age with a BSA of >1.3
5000 mikrograma (μg/ml) za bolesnike >2 godine starosti s površinom tijela >1,3
5000 ng/ml.
30 ng/ml do 5000 ng/ml.
50019 Sesto Fiorentino (FI) Italy.
50019 Sesto Fiorentino (FI) Italija
50019 Sesto Fiorentino, (FI) Italy.
50019 Sesto Fiorentino, (FI) Italija
500–1700 U1
500 – 1700 U1
50100 La Almunia de Doña Godina, Zaragoza, Spain
50100 La Almunia de Doña Godina, Zaragoza, Španjolska
50739 Köln GERMANY
Osterather Strasse 1a 50739 Köln NJEMAČKA
508
negativna
509 patients with advanced breast cancer who had not received prior chemotherapy for metastatic disease were treated with Caelyx (n=254) at a dose of 50 mg/m2 every 4 weeks, or doxorubicin (n=255) at a dose of 60 mg/m2 every 3 weeks, in a phase III clinical trial (I97-328).
U kliničkom ispitivanju faze III (I97-328), 509 bolesnica s uznapredovalim karcinomom dojke koje prethodno nisu primale kemoterapiju zbog metastatske bolesti bile su liječene Caelyxom (n=254) u dozi od 50 mg/m2 svaka 4 tjedna ili doksorubicinom (n=255) u dozi od 60 mg/m2 svaka 3 tjedna.
50x1 film-coated tablets
50x1 filmom obloženih tableta
50x1 hard capsules.
50 x 1 tvrda kapsula.
50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters.
50x1 tableta u PVC/PVDC/aluminij blisterima ili u perforiranim aluminijskim blisterima djeljivim na jedinične doze.
50×1 capsule
50×1 kapsula
50–60 3.5 mg* zoledronic acid
3,5 mg* zoledronatne kiseline
50–60 3.5 mg* zoledronic acid
50 – 60 3,5 mg* zoledronatne kiseline
51.5 to 53.3
51,5 do 53,3
51063 Cologne Germany
51063 Cologne Njemačka
5111 PV Baarle-Nassau NETHERLANDS
5111 PV Baarle-Nassau NIZOZEMSKA
5111 PV Baarle-Nassau The Netherlands
5111 PV Baarle-Nassau Nizozemska
51377 Leverkusen Germany
51377 Leverkusen Njemačka
51377 Leverkusen, Germany
51377 Leverkusen, Njemačka
52
N/Aa
52 % of the patients in AEGIS 1 and 33 % in AEGIS 2 had a disease flare in the previous 6 months.
52 % bolesnika u okviru skupine AEGIS 1 i 33 % u okviru skupine AEGIS 2 doživjelo je reaktivaciju bolesti u prethodnih 6 mjeseci.
52 tablets
52 tablete
52 tablets (13 blister strips with 4 tablets each) Not all pack sizes may be marketed.
52 tableta (13 blister traka s 4 tablete) Ne moraju sve veličine pakovanja biti u prometu.
52 Weeks
52. tjedan
52 weeks of treatment
52 tjedna liječenja
52 weeks of treatment
Liječenje u trajanju od 52 tjedna
52 weeks.
52 tjedna.
52% of patients with virologic failure in the rilpivirine arm developed concomitant NNRTI and NRTI mutations.
U skupini koja je primala rilpivirin, 52% pacijenata s virološkim neuspjehom istovremeno je razvilo mutacije na NNRTI i NRTI.
52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, France
52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, Francuska
52-week study whereas treatment with insulin was associated with weight gain.
52-tjednom ispitivanju, dok je liječenje inzulinom bilo udruženo s povećanjem težine.
52.6% (30/57)
Pbo/PR
52.9%
Zonisamid
523 patients with giant cell tumour of bone in single-arm, clinical trials examining the efficacy and safety of XGEVA.
523 bolesnika s gigantocelularnim tumorom kosti iz kliničkih ispitivanja na jednoj skupini bolesnika koja su ispitivala djelotvornost i sigurnost lijeka XGEVA.
525 mg (6.6 ml) twice daily
525 mg (6,6 ml) dva puta na dan
53 dogs were treated with Simparica for two months whilst 26 dogs were given a medicine containing moxidectin and imidacloprid.
53 pasa liječena su VMP-om Simparica tijekom dva mjeseca dok je 26 pasa primilo VMP koji je sadržavao moksidectin i imidakloprid.
53 p<0.0001
53 p<0,0001
53.4 to 55.2
53,4 do 55,2
53.7 (9.1 to -)
53,7 (9,1 do -)
53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e.
53,7%, međutim, podaci su pokazali da je većina novorođenčadi imala normalnu porođajnu tjelesnu težinu za svoju gestacijsku dob) kao i rizik od hiperkalijemije u novorođenčeta (incidencija od 8 na 111 novorođenčadi, tj.
53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e.
53,7%; međutim, podaci su pokazali da je većina novorođenčadi imala normalnu porođajnu težinu za gestacijsku dob), kao i od hiperkalijemije u novorođenčadi (incidencija je 8 na 111 novorođene djece, tj.
53018 Rosia Sovicille (SI) Italy.
53018 Rosia Sovicille (SI) Italija.
53018 Sovicille (Siena) Italy.
53018 Sovicille (Siena) Italija.
53100 Siena Italy.
53100 Siena Italija.
53119 Bonn Germany
53119 Bonn Njemačka
533 mg/133 mg twice daily
533 mg/133 mg 2 puta dnevno
533/133.3 mg twice daily
533/133,3 mg dva puta
533/133.3 mg twice daily
533/133,3 mg dva puta na dan
53773 Hennef Germany
53773 Hennef Njemačka
54 (18.2%)
Povratak na početno
54% (15/28)
Ciroza
54% (p<0.0001)
54 % (p<0,0001)
54, rue La Boétie - F-75008 Paris - France
54, rue La Boétie - F-75008 Pariz - Francuska
54, rue La Boétie F – 75008 Paris France
54, rue La Boétie F – 75008 Paris Francuska
54, rue La Boétie F-75008 Paris France
54, rue La Boétie - F-75008 Paris – Francuska
54, rue La Boétie F-75008 Paris France
F-75008 Pariz Francuska
54, rue La Boétie – F-75008 Paris France
54, rue La Boétie - F-75008 Pariz Francuska
54, rue La Boétie – F-75008 Paris France
54, rue La Boétie – F-75008 Paris Francuska
54.2
doze N=925
54.9 (p<0.0001)
54,9 (p<0,0001)
54.9% (45.4, 62.9)c fewer cases than injectable
54,9% (45,4; 62,9)c manje slučajeva nego s cjepivom koje se ubrizgava
54500 Vandoeuvre les Nancy France
54500 Vandoeuvre les Nancy Francuska
55% of the dose was excreted as unchanged migalastat, 4% as M1 to M3, and 5% was from unassigned components, for a total of 64%.
55% te doze bilo je izlučeno kao neizmijenjeni migalastat, 4 % kao M1 do M3, a 5 % bilo je od nedodijeljenih komponenata, što ukupno iznosi 64 %.
55%; P < .0001
55%; P < 0,0001
55.3 to 57.0
55,3 do 57,0
55216 Ingelheim am Rhein Germany
D-55216 Ingelheim am Rhein Njemačka
55216 Ingelheim GERMANY
55216 Ingelheim NJEMAČKA
5531 AE Bladel, The Netherlands
5531 AE Bladel, Nizozemska
56 (14 sachets of 4) ampoules
56 ampula (14 vrećica sa po 4 ampule)
56 (4 x 14) capsules (blister unit) + 1 Turbospin powder inhaler
56 (4 x 14) kapsula (blister jedinica) + 1 Turbospin inhalator za prašak
56 (7 x 8) capsules (blister unit) + 1 Turbospin powder inhaler
56 (7 x 8) kapsula (blister jedinica) + 1 Turbospin inhalator za prašak
56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for a 28 day supply)
56 kapsula (4 blister kartice od: 7 x 20 mg i 7 x 80 mg) (dnevna doza od 100 mg za primjenu tijekom
56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose)
56 kapsula (4 blister kartice od 7 x 20 mg i 7 x 80 mg) (100 mg/dnevna doza)
56 capsules + 1 inhaler
56 kapsula + 1 inhalator
56 coated tablets
56 obloženih tableta
56 Days after inactivated vaccinea
56 dana nakon primjene inaktiviranog cjepivaa
56 film-coated tablets (2 packs of 28 tablets).
56 filmom obloženih tableta (2 pakiranja po 28 tableta).
56 hard capsules and one Turbospin powder inhaler device sufficient for 4 weeks use.
56 tvrdih kapsula i jedan inhalator za prašak Turbospin, što je dovoljno za 4 tjedna primjene.
56 inhalation powder, hard capsules and 1 inhaler (weekly pack)
56 prašak inhalata, tvrdih kapsula i 1 inhalator (tjedno pakiranje)
56 mg of maltose per tablet
56 mg maltozu po tableti
56 paediatric PKU patients <4 years of age were randomized 1:1 to receive either 10 mg/kg/day Kuvan plus a phenylalanine-restricted diet (n=27), or just a phenylalanine-restricted diet (n=29) over a 26-week Study Period.
56 pedijatrijskih bolesnika s PKU u dobi <4 godine bilo je randomizirano u omjeru 1:1 u skupinu koja je primala Kuvan u dozi od 10 mg/kg na dan uz prehranu siromašnu fenilalaninom (n=27) ili skupinu koja je bila samo na prehrani siromašnoj fenilalaninom (n=29) tijekom 26 tjedana ispitivanja.
56 tablets
56 tablete
56 tablets (multipack)
56 tableta (višestruko pakiranje)
56 tablets (PA/Alu/PVC blisters)
56 tableta (PA/Al/PVC blisteri)
56 tablets (PVC/PCTFE blisters)
56 tableta (PVC/PCTFE blisteri)
56 tablets 56x1 tablet 90 tablets
56 tableta 56x1 tableta 90 tableta
56 tablets: EU/1/08/480/003
56 tableta: EU/1/08/480/003
56 tablets: EU/1/10/632/004
56 tableta: EU/1/10/632/004
56 tablets: EU/1/10/632/011
56 tableta: EU/1/10/632/011
56 tablets: EU/1/10/632/018
56 tableta: EU/1/10/632/018
56 tablets: EU/1/11/721/004
56 tableta: EU/1/11/721/004
56 tablets: EU/1/11/721/011
56 tableta: EU/1/11/721/011
56 tablets: EU/1/11/721/018
56 tableta: EU/1/11/721/018
56 tablets: EU/1/11/723/004
56 tableta: EU/1/11/723/004
56 tablets: EU/1/11/723/011
56 tableta: EU/1/11/723/011
56 tablets: EU/1/11/723/018
56 tableta: EU/1/11/723/018
56 x 1 capsules (unit
56 x 1 kapsula
56 x 1 capsules (unit
56 x 1 kapsula (jedinična doza)
56 x 1 capsules (unit dose)
56 x 1 kapsula (jedinična doza)
56 x 1 film-coated tablet
56 x 1 filmom obložena tableta (56x1)
56 x 1 film-coated tablets
56 x 1 filmom obložena tableta
56 x 1 film-coated tablets
56 x 1 filmom obloženih tableta
56 x 1 hard capsules
56 x 1 tvrda kapsula
56 x 1 tablet (unit dose)
56 x 1 tableta (jedinična doza)
56 x 1 tablets (unit
56 x 1 tableta
56 x 1 tablets (unit dose)
56 x 1 tableta (jedinična doza)
56 x 1 tablets (unit dose)
56 x 1 tableta (pakovanje s jediničnim dozama)
56 x 1 tablets: EU/1/08/480/004
56 x 1 tableta: EU/1/08/480/004
56 x 1 tablets: EU/1/08/480/010
56 x 1 tableta: EU/1/08/480/010
56 x 1 tablets: EU/1/08/480/016
56 x 1 tableta: EU/1/08/480/016
56 x 1, 60, 70, 70 x 1, 98 or 98 x 1 film-coated tablets per carton.
56, 56 x 1, 60, 70, 70 x 1, 98 ili 98 x 1 filmom obloženih tableta.
56 x1 film-coated tablet
56 x 1 filmom obložena tableta
56 x1 tablet
56 x1 tableta
56% of the patients have been free of hypopigmentation; hyperpigmentation has not been reported.
Hiperpigmentacija nije zabilježena.
56.4 [45.1, 76.9] (n = 131)
P-vrijednostb
56.4 years; for women 53.5 years) treated with > 7.5 mg/day oral prednisone (or equivalent).
833 muškaraca i žena u dobi od 18-85 godina (srednja dob za muškarce 56,4 godine; za žene 53,5 godine) liječenih s >7,5 mg/dan peroralnog prednizona (ili ekvivalenta).
56.4% tiotropium, p=0.047), and at week 64 compared to glycopyrronium and tiotropium (57.3% Ultibro Breezhaler versus 51.8% glycopyrronium, p=0.055; versus 50.8% tiotropium, p=0.051, respectively).
56,4% tiotropij, p=0,047), te u 64 tjednu u usporedbi s glikopironijem i tiotropijem (57,3% Ultibro Breezhaler u odnosu na 51,8% glikopironij, p=0,055; naspram 50,8% tiotropij, p=0,051).
56.4% tiotropium, p=0.047), and at week 64 compared to glycopyrronium and tiotropium (57.3% Ulunar Breezhaler versus 51.8% glycopyrronium, p=0.055; versus 50.8% tiotropium, p=0.051, respectively).
56,4% tiotropij, p=0,047), te u 64 tjednu u usporedbi s glikopironijem i tiotropijem (57,3% Ulunar Breezhaler u odnosu na 51,8% glikopironij, p=0,055; naspram 50,8% tiotropij, p=0,051).
56.4% tiotropium, p=0.047), and at week 64 compared to glycopyrronium and tiotropium (57.3% Xoterna Breezhaler versus 51.8% glycopyrronium, p=0.055; versus 50.8% tiotropium, p=0.051, respectively).
56,4% tiotropij, p=0,047), te u 64 tjednu u usporedbi s glikopironijem i tiotropijem (57,3% Xoterna Breezhaler u odnosu na 51,8% glikopironij, p=0,055; naspram 50,8% tiotropij, p=0,051).
56.6 (48.7 to 68.4)
56,6 (48,7 do 68,4)
56x1 film-coated tablet (unit dose) 98x1 film-coated tablet (unit dose) 280x1 film-coated tablet (unit dose)
56x1 filmom obloženih tableta (jedinična doza) 98x1 filmom obloženih tableta (jedinična doza) 280x1 filmom obloženih tableta (jedinična doza)
56x1 tablets (unit dose)
56x1 tableta (jedinična doza)
57 (45)d
0 (0)
57 (52, 62)
Parametar
57 mg lactose per tablet
57 mg laktoze po tableti
57% of normal)
57 % normalne vrijednosti)
57.1b
60,1
57.8% (37/64)
Relaps
58 IU/kg)
30 IU/kg
58-500 Jelenia Góra, Poland
58-500 Jelenia Góra, Poljska
58.1 (45.6 to 82.1)
58,1 (45,6 do 82,1)
58.5 kg and above
58,5 kg i više Najviša
58.8 micrograms
58,8 mikrograma
5831 AN Boxmeer The NETHERLANDS
Wim de Körverstraat 35 5831 AN Boxmeer NIZOZEMSKA
59 (46, 71)
Placebo +
59 days
59 dana
59 mL/min/1.73 m2) approximately 1.5-fold and 1.8-fold, respectively, compared with healthy subjects.
59 ml/min/1,73 m2) je oko 1,5 puta, a AUC nevezanog ertapenema oko 1,8 puta veći nego u zdravih ispitanika.
59% (p<0.0001)
59 % (p<0,0001)
59% of patients with a phakic study eye required cataract surgery by the 3 year final visit, with the majority performed in the 2nd and 3rd years.
Na završnom pregledu nakon trogodišnjeg ispitivanja, u 59% bolesnika utvrđena je potrebna operacija katarakte na fakičnom ispitivanom oku, a većina tih operacija obavljena je u 2. i 3. godini.
59, clădirea HQ Sector 1, 010623, Bucureşti,
59, clădirea HQ
5928 LC Venlo The Netherlands
5928 LC Venlo Nizozemska
593 08740 Sant Andreu de la Barca Barcelona
08740 Sant Andreu de la Barca Barcelona
59390 Lys-Lez-Lannoy France
59390 Lys-Lez-Lannoy Francuska
5A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
5 Provedena je analiza objedinjenih podataka o prijelomima kostiju kao nuspojavama u randomiziranim, usporednim lijekom kontroliranim, dvostruko slijepim kliničkim ispitivanjima u više od 8100 bolesnika u skupinama liječenima pioglitazonom i 7400 bolesnika u skupinama liječenima usporednim lijekom u trajanju do 3,5 godine.
5according to protocol
5prema planu ispitivanja
5all subjects seronegative prior to vaccination
5svi ispitanici koji su prije cijepljenja bili seronegativni
5b) To ensure haemostasis, immediately apply manual compression over the entire surface of the EVARREST (including the area of overlap) sufficient to stem all bleeding.
5b) Da biste postigli hemostazu odmah primijenite ručnu kompresiju preko cijele površine lijeka EVARREST (uključujući područje preklapanja rubova) dostatno da se zaustavi krvarenje.
5mg ceftiofur/kg bodyweight (equivalent to 1ml of NAXCEL per 20kg bodyweight) administered once in the neck by intramuscular injection.
5 mg ceftiofura/kg tjelesne težine (odgovara 1 ml NAXCELA na 20 kg tjelesne težine) primijenjeno jedanput u vrat intramuskularnom injekcijom.
5mg tablets
5 mg tablete
5ml vial, cartridge, cartridge for OtiClik, Optiset pre-filled pen, SoloStar pre-filled pen, Zinc chloride
Bočica od 5 ml, uložak, uložak za OptiClik, napunjena brizgalica OptiSet, napunjena brizgalica SoloStar
5patients responded, 3 completely and 2 partially.
5 bolesnika je imalo odgovor, 3 potpuni i 2 djelomični.
5patients responded, 3 completely and 2 partially.
5 bolesnika je imalo odgovor, 3potpuni i 2 djelomični.
5th Floor Hayes
Hayes
5th year of life
5. godina života
5x1 hard capsules 20x1 hard capsules
5x1 tvrdih kapsula 20x1 tvrdih kapsula
5x20 ml solution for infusion
5x20 ml otopina za infuziju
5“+” indicates an ongoing response.
5"+" označava odgovor koji još traje.
5”, “10”,”20”, “40”, “80” or “120”.
5", "10", "20", "40", "80" ili "120".
6 (1.9)
Pretrage
6 (2 packs of 3) pre- filled pens (multipack)
6 (2 pakovanja od 3) napunjenih brizgalica (višestruko pakovanje)
6 (3 x 2) pre-filled pens (multipack)
6 (3 x 2) napunjenih brizgalica (višestruko pakiranje)
6 (3 x 2) pre-filled syringes (multipack)
6 (3 x 2) napunjenih štrcaljki (višestruko pakiranje)
6 - 12 months (n=202)
6 - 12 mjeseci (n=202)
6 000 IU/0.6 ml
6000 IU/0,6 ml
6 A pooled analysis was conducted of adverse event reports of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
6 Provedena je analiza objedinjenih podataka o prijelomima kostiju prijavljenih kao štetan događaj u randomiziranim, dvostruko slijepim kliničkim ispitivanjima kontroliranima komparatorom u više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih komparatorima u trajanju do najviše 3,5 godine.
6 Adverse reactions (frequency and seriousness)
Nuspojave (učestalost i ozbiljnost)
6 alcohol wipes for skin and vial cleaning
6 tupfera natopljenih alkoholom za čišćenje kože i bočice
6 alcohol wipes for skin and vial cleaning
6 tupfera natopljenih alkoholomza čišćenje kože i bočice
6 Aluminium blisters each containing one 165 mg capsule
6 aluminijskih blistera, svaki s jednom kapsulom od 165 mg
6 applicators
6 Aplikatora
6 bottles
6 boca
6 bottles
6 bocas
6 bottles
6 boce
6 bottles
6 bočica
6 capsules
6 kapsula
6 cartridges
5 uložaka
6 cartridges
6 uložaka
6 cartridges of 3ml.
6 uložaka od 3 ml.
6 Cases of worsening dyspnoea of unclear aetiology have been reported shortly after starting ambrisentan therapy.
6 slučajevi pogoršanja dispneje nepoznate etiologije, zabilježeni su kratko nakon početka terapije ambrisentanom
6 cm Flexible Tip
savitljivi nastavak duljine 6 cm
6 Content of the pack and other information
Sadržaj pakiranja i druge informacije
6 Contents of the pack and other information What AZOPT contains
Sadržaj pakiranja i druge informacije Što AZOPT sadrži
6 Contents of the pack and other information What Cerezyme contains
Sadržaj pakiranja i druge informacije Što Cerezyme sadrži
6 Contents of the pack and other information What EMADINE contains
6 Sadržaj pakiranja i druge informacije Što EMADINE sadrži
6 Contents of the pack and other information What Epivir contains
Sadržaj pakiranja i druge informacije Što Epivir sadrži
6 cycles of TCH in combination with Perjeta.
6 ciklusa TCH-a u kombinaciji s lijekom Perjeta
6 days.
6 dana.
6 Emtricitabine/tenofovir alafenamide was taken with food in this study.
6 U ovom se ispitivanju emtricitabin/tenofoviralafenamid uzimao s hranom
6 Final overall survival analysis performed when 46.9% of the patients had died.
6 Finalna analiza ukupnog preživljenja izvršena je nakon što je umrlo 46,9% bolesnica.
6 Fisher’s exact test
6 Fisherov egzaktni test
6 hours after application
6 sati nakon primjene
6 hours after raltegravir
6 sati nakon raltegravira
6 hours before raltegravir
6 sati prije raltegravira
6 hours until the next dose, in which case the patient should not take the missed dose.
U tom slučaju bolesnik ne smije uzeti propuštenu dozu.
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
6 U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2–3 kg tijekom jedne godine.
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2–3 kg over one year.
6 U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2–3 kg tijekom jedne godine.
6 In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
Međutim, incidencija smrtnosti bila je veća u bolesnika liječenih olanzapinom nego u bolesnika liječenih placebom, neovisno o ovim čimbenicima rizika.
6 Includes Dry skin, Skin chapped
6 uključuje suhu kožu, raspucanu kožu
6 Includes Pruritus, Pruritus generalised
6 uključuje pruritus, generalizirani pruritus
6 Including fatalities.
6 uključujući smrtne slučajeve.
6 kg to less than 8 kg
6 kg do manje od 8 kg
6 kg to less than 8 kg
od 6 kg do manje od 8 kg
6 Metformin was uptitrated from 500 to 2000 mg per day as tolerated.
6 Doza metformina titrirana je na višu od 500 do 2000 mg a dnevno, ovisno o podnošljivosti.
6 mg once daily5
dasabuviru i potrebno ga
6 mg/kg every 12hours
6 mg/kg svakih
6 mg/kg every 48 hours
6 mg/kg svakih 48 sati
6 mg/kg once daily
6 mg/kg jedanput na dan
6 MIU/m2/week in hairy cell leukaemia up to 100 MIU/m2/week in melanoma), the most commonly reported undesirable effects were pyrexia, fatigue, headache and myalgia.
6 milijuna IU/m2 na tjedan u liječenju leukemije vlasastih stanica do 100 milijuna IU/m2 na tjedan u liječenju melanoma), najčešće prijavljene nuspojave bile su pireksija, umor, glavobolja i mialgija.
6 ml clear glass Type I vial with a bromobutyl rubber stopper and a flip-off cap.
Prozirna staklena bočica od 6 ml (staklo tip I), s čepom od bromobutilne gume i s "flip-off" zatvaračem.
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a blue flip-off aluminium over seal containing 4 ml of concentrate.
Prozirna bezbojna staklena bočica od 6 ml (staklo tip I) s 1 ml koncentrata, zatvorena gumenim (flurotec) čepom i plavim “flip-off” aluminijskim zaštitnim zatvaračem.
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a green flip-off aluminium over seal containing 1 ml of concentrate.
Prozirna bezbojna staklena bočica od 6 ml (staklo tip I) s 1 ml koncentrata, zatvorena gumenim (flurotec) čepom i zelenim „flip-off“ aluminijskim zaštitnim zatvaračem.
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a red flip-off aluminium over seal containing 6 ml of concentrate.
Prozirna bezbojna staklena bočica od 6 ml (staklo tip I) sa 6 ml koncentrata, zatvorena gumenim (flurotec) čepom i crvenim “flip-off” aluminijskim zaštitnim zatvaračem.
6 ml, glass vial (type I) with fluorotec plus rubber stopper and aluminium seals with lavender flip-off cap.
6 ml, staklena bočica (staklo tipa I) s „fluorotec plus“ gumenim čepom i aluminijskim prstenom s „flip- off“ kapicom boje lavande.
6 ml, glass vial (type I) with fluorotec plus rubber stopper and aluminium seals with pink flip-off cap.
6 ml, staklena bočica (staklo tipa I) s „fluorotec plus“ gumenim čepom i aluminijskim prstenom s rozom „flip-off“ kapicom.
6 ml, glass vial (type I) with fluorotec plus rubber stopper and aluminium seals with pink flip-off cap.
Staklena bočica od 6 ml (staklo tip I), s „fluorotec plus“ gumenim čepom i aluminijskim prstenom s rozom „flip-off“ kapicom.
6 ml, type I clear glass vial or 5 ml plastic vial, stoppered with a fluoropolymer-coated halo-butyl closure and sealed with an aluminium seal and flip-off top.
Prozirna staklena bočica tipa I od 6 ml ili plastična bočica od 5 ml, zatvorene halobutilnim čepom obloženim flourpolimerom, aliminijskim prstenom i ˝flip-off˝ poklopcem.
6 ml/10 ml vial
6 ml/10 ml Staklena bočica
6 months (5.5, 8.7)
6 mjeseci (5,5, 8,7)
6 months = 5x half-life for immunoglobulins).
6 mjeseci = 5 x poluvijek imunoglobulina).
6 months after
6 mjeseci nakon cijepljenja
6 months after the 1st dose N=256
6 mjeseci nakon
6 months age.
8 bolesnika nakon dobi od 6 mjeseci.
6 months in line with the periodic safety update report (PSUR) cycle
podatke CHMP-u svakih 6 mjeseci u skladu s ciklusom perdiodičkih
6 months in pigs vaccinated for the first time at 96 days and above.
6 mjeseci kod svinja cijepljenih prvi puta u dobi od 96 dana i starijih.
6 months survival rate
6-mjesečna stopa preživljenja
6 months –
6 mjeseci